Assistance Publique - Hopitaux De Paris Patent applications |
Patent application number | Title | Published |
20160130346 | KIR3DL2 IS A BIOMARKER AND A THERAPEUTIC TARGET USEFUL FOR RESPECTIVELY PREVENTING AND TREATING A SUBSET OF CUTANEOUS AND NON-CUTANEOUS PERIPHERAL T-CELL LYMPHOMAS - The present invention relates to a ligand molecule that specifically binds to KTR3DL2 at the surface of KTR3DL2 expressing malignant T-cells for the treatment of lymphomas. It also relates to the in vitro use of a level of expression of KIR3DL2 is a biomarker useful for diagnosing and/or monitoring a lymphoma. | 05-12-2016 |
20160074369 | BIOTIN FOR USE IN TREATING X-LINKED ADRENOLEUKODYSTROPHY - The invention relates to the use of biotin for treating X-linked adrenoleukodistrophy, in particular adrenomyeloneuropathy. | 03-17-2016 |
20160030394 | Mazindol Combination In The Treatment Of Attention-Deficit/Hyperactivity - The present invention relates to the field of human health, and more particularly to the treatment of attention deficit/hyperactivity disorder (ADHD) with mazindol. The latter can be administered as monotherapy or in combination with one or more compounds, including psychostimulants, for the indication of ADHD and associated or co-morbid symptoms. | 02-04-2016 |
20160004828 | Method for Assessing Activity of an Autoinflammatory Disease - The invention relates to a method for determining the activity of an autoinflammatory disease in a patient, where a patient reports the status of at least 5 dichotomous items corresponding to a physiological observation and the values of each status is combined in a mathematical function to obtain an end value. | 01-07-2016 |
20150369811 | METHODS FOR PREDICTING THE SURVIVAL TIME OF A PATIENT SUFFERING FROM A SOLID CANCER - The present invention provides methods and kits for the prognosis of survival time of a patient suffering from a cancerous tumor. The method involves quantitating the density of Th17 cells at the center of the tumor and at the invasive margin of the tumor, where low density values at each location indicate a favourable prognosis, high values at each location indicate an unfavourable prognosis, and heterogeneous values at the two locations (one high, one low) indicate an intermediate prognosis. | 12-24-2015 |
20150323535 | METHOD FOR DIAGNOSING NEURODEGENERATIVE DISEASES - The present invention relates to a method for diagnosing, in vitro, a neurodegenerative disease in an individual, in which: the level of the double-stranded RNA-dependent protein kinase (PKR) in a sample of cerebrospinal fluid from the individual is determined; it is deduced therefrom whether the individual is suffering from a neurodegenerative disease. | 11-12-2015 |
20150307593 | METHODS FOR DIAGNOSING AND/OR TREATING STERILITY - The present invention concerns a polypeptide comprising the N-terminal fragment of a cystatin, and/or a cystatin expression inducer for use for the treatment of sterility and/or infertility, and a method of diagnosing and/or predicting sterility and/or infertility of a subject and/or of a couple of subjects, which method comprises measuring the level of at least one cystatin in a biological sample of a male subject and/or measuring the level of at least one cystatin in a biological sample of a female subject, and optionally measuring further the level of at least one cathepsin in a biological sample of said male of female subject. | 10-29-2015 |
20150301022 | METHODS FOR DETERMINING THE RISK OF ACUTE GRAFT VERSUS HOST DISEASE - The present invention relates to a method for determining whether a candidate human transplant donor is at risk of inducing acute graft versus host disease (aGVHD) in a human transplant recipient, which may in turn allow the selection of a donor exhibiting no risk for the recipient. The present invention also relates to a method for adjusting the immunosuppressive treatment administered to a human transplanted recipient following its graft transplantation after having performing the method for determining risk of the invention. The methods comprise expanding the candidate donor's iNKT cells (invariant NKT cells) and determining the presence or absence of expansion of the CD4(−) iNKT cell sub-population. In particular, CD3+CD4− TCRV[alpha]24V[beta]11 cells are determined. Kits are disclosed. | 10-22-2015 |
20150293126 | Method for Diagnosing a Hemoglobin-Related Disorder - The invention relates to a method for diagnosing, staging and/or monitoring a hemoglobin-related disorder such as β-thalassemia or a treatment against said hemoglobin-related disorder in a subject in need thereof based on the detection and/or quantification the presence of free α-Hb pool in a biological sample obtained from said subject. | 10-15-2015 |
20150225799 | METHODS FOR PREDICTING THE OUTCOME OF A CANCER IN A PATIENT BY ANALYSING GENE EXPRESSION - The present invention relates to a method for predicting the outcome of a cancer in a patient by analysing gene expression in a sample obtained from said patient. More particularly the present invention relates to a method for predicting the outcome of a cancer comprising a step consisting of determining the expression level of a gene cluster consisting of at least 3 genes in a sample obtained from said patient. | 08-13-2015 |
20150191276 | DEVICE FOR THE COLLECTION, PRE-ANALYTIC TREATMENT, TRANSPORT AND GRINDING OF SOLID SAMPLES - The invention relates to a device for the collection, pre-analytic treatment, transport and grinding of solid samples, comprising a flask ( | 07-09-2015 |
20150141850 | BALLOON CATHETER FOR MEASURING THE LENGTH OF A STENOSIS - A balloon catheter adapted for cooperating with an endoscope, the balloon catheter including a catheter shaft, a balloon located at a catheter shaft tip, wherein the catheter shaft includes visual markers designed for determining the length of a stenosis in a bodily structure. | 05-21-2015 |
20150140010 | METHODS FOR DIAGNOSING AND TREATING FOCAL SEGMENTAL GLOMERULOSCLEROSIS - The present invention relates to methods for diagnosing and treating focal segmental glomerulosclerosis. More particularly, the present invention relates to a method for determining whether a subject is at risk of having or developing a focal segmental glomerulosclerosis (FSGS) comprising the step consisting of determining the level of calcium/calmodulin-dependent serine protein kinase (CASK) in a blood sample obtained from the subject. The present invention also relates to an agent effective to inhibit the binding of CASK to hCD98 present on the surface of podocytes for use in the prevention or treatment of focal segmental glomerulosclerosis (FSGS) in a subject in need thereof. | 05-21-2015 |
20150119745 | METHOD FOR CHARACTERISING THE PHYSIOLOGICAL STATE OF A PATIENT FROM THE ANALYSIS OF THE CEREBRAL ELECTRICAL ACTIVITY OF SAID PATIENT, AND MONITORING DEVICE APPLYING SAID METHOD - The invention relates to a method for detecting a physiological state of a patient deviating from a reference physiological state, in which, after having determined, in each of Q frequency bands, R reference matrices PR | 04-30-2015 |
20150111951 | METHODS FOR THE TREATMENT OF LEBER CONGENITAL AMAUROSIS - The present invention relates to a method for treating a Leber congenital amaurosis in a patient harbouring the mutation c.2991+1655 A>G in the CEP290 gene, comprising the step of administering to said patient at least one antisense oligonucleotide complementary to nucleic acid sequence that is necessary for preventing splicing of the cryptic exon inserted into the mutant c.2291+1655 A>G CEP290 mRNA | 04-23-2015 |
20150065374 | Detection of Platelet-Derived Shed CD31 - The present invention relates to various soluble forms of CD31, including a novel form which is shed by activated platelets and released into the circulation. Methods for detecting said soluble forms of CD31 are disclosed, as are methods of specifically 1 detecting said platelet-derived shed CD31 and the use of such methods as a diagnostic tool. | 03-05-2015 |
20150017203 | COMBINATION PRODUCT FOR TREATING EXCESS WEIGHT AND/OR FOR IMPROVING THE FIGURE - A combination product includes as active substances, at least an inhibitor of the HMG-CoA-reductase enzyme and citrulline, or a bioequivalent compound thereof, for treating excess weight or obesity and/or the accumulation of body fat. A cosmetic treatment method for improving or slimming the figure and/or for stimulating the loss of excess weight and/or of cellulite and/or for limiting the accumulation thereof, includes the administration of a combination product including as active substances, at least an inhibitor of the HMG-CoA-reductase enzyme or a physiologically acceptable salt thereof, and citrulline, or a bioequivalent compound thereof, or one of theirs analogues, and the renewal of the administration until the expected cosmetic effect is obtained. The combination product such as previously defined for improving or slimming the figure and/or for stimulating the loss of excess weight and/or of cellulite and/or for limiting the accumulation thereof is also described. | 01-15-2015 |
20140371082 | PROCESS AND APPARATUS FOR QUANTIFYING NUCLEIC ACID IN A SAMPLE - In one aspect, the present invention concerns methods and kits for quantifying a target nucleic acid in a sample. In embodiments, a method comprises sequestrating the target nucleic acid by one or more interactors to form a sequestered conjugate that will be further labeled to form a labeled conjugate. The signal produced by the labeled conjugate is measured and correlated to the amount of the target nucleic acid. In another aspect, the present invention concerns a method for quantifying a target nucleic acid in a sample by a reaction of the nucleic acids in the sample with a nucleic acid interactor or set of interactors to form a conjugate. The conjugate is then sequestered from the rest of the sample with a molecule bound to a support, to form a sequestered conjugate. The sequestered conjugate is labeled to form a labeled conjugate. The signal produced by the labeled conjugate is measured and correlated to the amount of the target nucleic acid. In some embodiments, the target nucleic acid is cell free nucleic acids. In embodiments, the interactor binds to nucleic acids in the sample in a nonsequence specific manner. | 12-18-2014 |
20140368633 | DEVICE FOR VIEWING A DIGITAL IMAGE - The invention relates to a device for viewing a digital image comprising means ( | 12-18-2014 |
20140348920 | Method of Treating Multiple Sclerosis - The invention provides methods for treating multiple sclerosis by administering biotin. The invention also provides methods for treating sequelae after multiple sclerosis attacks by administering biotin. | 11-27-2014 |
20140335119 | POLYPEPTIDE DERIVED FROM gp41, A VACCINE COMPOSITION COMPRISING SAID POLYPEPTIDE, AND USES FOR TREATING AN INFECTION BY AN HIV VIRUS IN AN INDIVIDUAL - The present invention relates to the field of the in vitro diagnosis of the progression status of an infection of an individual with a virus belonging to the family of the Human Immunodeficiency Viruses (HIV) as well as with the therapeutical treatment of this infectious disease. The invention also relates to immunological compounds and vaccine compositions comprising a polypeptide derived from gp41. | 11-13-2014 |
20140329260 | METHOD OF DIAGNOSIS OF FIBROTIC DISEASES - The present invention relates to a new diagnosis method in the field of hepatology, combining measurement of serum markers and of liver elasticity. | 11-06-2014 |
20140302498 | RAPID DETECTION OF THE "HIGH VIRULENT" ST-17 CLONE OF GROUP B STREPTOCOCCUS - The present invention relates to polynucleotides enabling the rapid, simple and specific detection of Group B | 10-09-2014 |
20140249204 | IDENTIFICATION OF A JAK2 MUTATION IN POLYCYTHEMIA VERA - The present invention concerns the V617F variant of the protein-tyrosine kinase JAK2, said variant being responsible for Vaquez Polyglobulia. The invention also relates to a first intention diagnostic method for erythrocytosis and thrombocytosis allowing their association with myeloproliferative disorders, or to the detection of the JAK2 V617F variant in myeloproliferative disorders allowing their reclassification in a new nosological group. | 09-04-2014 |
20140205630 | COMPOSITIONS COMPRISING A B SUBUNIT OF SHIGA TOXIN AND A MEANS STIMULATING NKT CELLS - The present invention relates to a composition comprising a) a B subunit of Shiga toxin or a functional equivalent thereof which is able to bind the Gb3 receptor, complexed with an antigen and b) at least one ligand of CDl capable of stimulating NK T cells; and to a pharmaceutical composition and a medicament comprising said composition. | 07-24-2014 |
20140199379 | COMPOSITIONS HAVING MEANS FOR TARGETING AT LEAST ONE ANTIGEN TO DENDRITIC CELLS - A composition that can be used as a vaccine containing means for targeting at least one antigen to dendritic cells and as adjuvants a granulocyte macrophage colony stimulating factor and a CpG oligodeoxynucleotide and/or a CpG-like oligodeoxynucleotide. This composition can used to treat cancers, infectious diseases caused by bacterial, viral, fungal, parasitic or protozoan infections, allergies and/or autoimmune diseases. | 07-17-2014 |
20140178922 | SELECTIVE CULTURE MEDIUM AND METHOD FOR DETECTING CARBAPENEM-RESISTANT BACTERIA IN A TEST SAMPLE - The present invention relates to a culture medium comprising a carbapenem, a carbapenemase activator and a M-type penicillin. It also relates to a method for detecting carbapenem-resistant bacteria in a test sample using said culture medium. | 06-26-2014 |
20140170771 | MID-REGIONAL PRO-ATRIAL NATRIURETIC PEPTIDE (PRO-ANP) FOR THE IDENTIFICATION OF PATIENTS WITH ATRIAL FIBRILLATION WITH AN ONSET OF LESS THAN 48 HOURS AGO - The invention relates to a method for the determination of the time from onset of atrial fibrillation to presentation in a patient comprising the steps of: providing a sample of a bodily fluid of said patient, determining the level of proANP (SEQ ID NO: 1) or fragments thereof in said sample, correlating the level of proANP or fragments thereof to the time from the onset of atrial fibrillation to presentation of said patient, wherein said fragments have a length of at least 6 amino acid residues. | 06-19-2014 |
20140155731 | METHOD FOR IDENTIFYING NEUROPROTECTIVE COMPOUNDS AND/OR NEUROREGENERATION STIMULATORS BY FRACTIONAL ANISOTROPY MEASUREMENTS BY DIFFUSION-BASED MRI SCANNING - The present invention relates to a method for monitoring the effectiveness of a treatment on neuroprotection and to a method for identifying candidate molecules that are neuroprotectors and/or neuronal growth stimulators. The present invention can be used, in particular, in the field of pharmaceutics, in the field of scientific research and in the field of clinical trials and validation of therapeutic substances. | 06-05-2014 |
20140134656 | METHOD FOR DETECTING THE PRESENCE OF CARBAPENEMASE-PRODUCING BACTERIA IN A SAMPLE - The present invention relates to a method for detecting the presence of carbapenemase-producing bacteria in a sample, said method comprising the steps of: a) performing cell lysis on a test sample in order to obtain an enzymatic suspension; b) reacting a fraction of the enzymatic suspension obtained in step a) with a reagent kit, said reagent kit comprising —a carbapenemase substrate selected from the group consisting of carbapenems and cephamycins, —a pH color indicator which will change color when the pH of the reaction mixture is comprised between 6.4 and 8.4, wherein a color change after step b) indicates the presence of carbapenemase-producing bacteria in the test sample. The invention also relates to a reagent kit, to a microtiter plate and to their uses in detecting the presence of carbapenemase producers in a test sample. | 05-15-2014 |
20140120088 | AGENTS FOR THE TREATMENT OF TUMORS - The invention relates to the treatment of patients with a brain tumor or neoplastic meningitis, by the use of an agonist of the TLR9 receptor in combination with an anti-angiogenic product. | 05-01-2014 |
20140087387 | Methods for the Treatment, the Prognostic Assessment and the Staging of Non-Small Cell Lung Cancer - The present invention relates to methods for the treatment, the prognosis and the diagnosis of non-small cell lung cancer. | 03-27-2014 |
20140080875 | 3,4-DIAMINOPYRIDINE TARTRATE AND PHOSPHATE, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF - The invention relates to 3,4-diaminopyridine salts, pharmaceutical compositions containing at least one of said salts and uses thereof for the treatment of botulism, myasthenia, myasthenic syndromes or fatigue. | 03-20-2014 |
20140051761 | KATP ANTAGONISTS (GLIBENGLAMID) FOR USE FOR PROMOTING GROWTH AND/OR TREATING HYPERGLYCAEMIA OF A PREMATURE INFANT - The present invention relates to pharmaceutical compositions comprising an ATP-sensitive potassium (K ATP) channel antagonist (e.g., sulfonylureas, meglitinides) and methods for treating hyperglycaemia and/or promoting growth of a premature and/or small for gestational age infant. | 02-20-2014 |
20140046213 | DEVICE FOR ASSISTING WITH THE SAMPLING OF A BIOLOGICAL FLUID PRESENT IN A CAVITY - A device for assisting with the sampling of a biological fluid present in a cavity, which device can co-operate with a puncture needle, the device including a holding member for keeping the device and the needle rigidly connected to one another while the needle is being inserted into the cavity; and a securing device which, following the introduction of the needle into the cavity, can be secured to an internal wall of the cavity. | 02-13-2014 |
20140031633 | FOUR-VALVE VAGINAL SPECULUM - A vaginal speculum includes a first rod supporting a first arm that is slidable along the first rod, a first valve being attached to the first arm, and a second arm, a second valve being attached to the second arm. The vaginal speculum further includes a second rod supporting a third arm that is slidable along the second rod, a third valve being attached to the third arm, and a fourth arm, a fourth valve being attached to the fourth arm. The first rod and the second rod are rigidly connected to one another. | 01-30-2014 |
20140030733 | Method for Diagnosing Neurodegenerative Diseases - The present invention relates to a method for diagnosing, in vitro, a neurodegenerative disease in an individual, in which:—the level of the double-stranded RNA-dependent protein kinase (PKR) in a sample of cerebrospinal fluid from the individual is determined,—it is deduced therefrom whether the individual is suffering from a neurodegenerative disease. | 01-30-2014 |
20140030331 | METHOD OF TREATING MULTIPLE SCLEROSIS - The invention provides methods for treating multiple sclerosis by administering biotin. The invention also provides methods for treating sequalae after multiple sclerosis attacks by administering biotin. | 01-30-2014 |
20140018255 | METHODS FOR PREDICTING THE OUTCOME OF A CANCER IN A PATIENT BY ANALYSING GENE EXPRESSION - The present invention relates to a method for predicting the outcome of a cancer in a patient by analysing gene expression in a sample obtained from said patient. More particularly the present invention relates to a method for predicting the outcome of a cancer comprising a step consisting of determining the expression level of a gene cluster consisting of at least 3 genes in a sample obtained from said patient. | 01-16-2014 |
20130344160 | IMPLANTABLE BIO-RESORBABLE POLYMER CHARGED WITH FRAGILE MACROMOLECULES - The present invention relates to a macromolecule-loaded bioresorbable crosslinked polymer wherein the polymer is obtainable from the polymerization of: (i) at least one monomer of formula (I) (CH | 12-26-2013 |
20130344159 | IMPLANTABLE SWELLABLE BIO-RESORBABLE POLYMER - The present invention relates to a polymer obtained from the polymerization of: (i) at least one monomer of formula (I) (CH | 12-26-2013 |
20130323217 | COMPOSITIONS AND METHODS FOR THE CONTROLLED REPOPULATION OF GRAM-NEGATIVE BACTERIA IN THE COLON - The present invention relates to a method for the controlled repopulation of the colonic bacterial flora. | 12-05-2013 |
20130316332 | COMBINATION OF BIOMARKERS FOR THE PROGNOSIS OF RESPONSE OR NON-RESPONSE TO AN ANTI-HCV TREATMENT - The application concerns means for predicting whether a subject infected with one or more HCVs has a high probability of responding to an anti-HCV treatment which will comprise the administration of interferon and of ribavirin or whether, in contrast, that subject has a high probability of not responding to that anti-HCV treatment. The means of the invention in particular involve assaying the levels of expression of selected genes, said selected genes being:
| 11-28-2013 |
20130295196 | LAUFLUMIDE AND THE ENANTIOMERS THEREOF, METHOD FOR PREPARING SAME AND THERAPEUTIC USES THEREOF - The invention relates to the molecule having formula (I), as well as the enantiomers thereof, and to the use of same in the treatment of ADHD, narcolepsy or idiopathic hypersomnia. | 11-07-2013 |
20130288918 | Colorectal Cancer Screening Method - The invention relates to a method of screening for colorectal cancer in a subject, comprising a step of measuring the degree of methylation of at least one of the genes selected from NPY, PENK and fragments or variants thereof in a biological sample obtained from said subject. | 10-31-2013 |
20130204316 | APPARATUS FOR THE TREATMENT OF BRAIN AFFECTIONS AND METHOD IMPLEMENTING THEREOF - The present invention relates to an apparatus for the treatment of a brain affection, which comprises at least one implantable generator ( | 08-08-2013 |
20130204150 | SYSTEM FOR ELECTROENCEPHALOGRAPHIC DETECTION OF AN INADEQUACY BETWEEN THE STATE OF A PATIENT PLACED UNDER VENTILATORY SUPPORT AND THE SETTING OF THE MACHINE USED FOR THIS SUPPORT, AND USE OF THIS DETECTION TO ADJUST THE SETTING - The invention relates to a system for electroencephalographic detection of an improper adjustment of a ventilator used on a mammal. The system includes an electroencephalograph, capable of measuring, as a function of time, an electroencephalographic signal representative of a breathing process; and an input for receiving a respiratory initiation signal, different from the electroencephalographic signal, capable of indicating a respiratory initiation time. The detection system further includes means for specifying a beta frequency band comprised between 15 and 30 Hz and with a width comprising between 5 and 10 Hz; means for processing the measured electroencephalographic signal, configured for processing the measured electroencephalographic signal as it is being acquired, in the sole specified beta frequency band; and means for identifying, for each breathing cycle, an improper adjustment of the ventilator from the electroencephalographic signals processed in the sole beta frequency band. | 08-08-2013 |
20130189683 | IDENTIFICATION OF A JAK2 MUTATION INVOLVED IN VAQUEZ POLYGLOBULIA - The present invention concerns the V617F variant of the protein-tyrosine kinase JAK2, said variant being responsible for Vaquez Polyglobulia. The invention also relates to a first intention diagnostic method for erythrocytosis and thrombocytosis allowing their association with myeloproliferative disorders, or to the detection of the JAK2 V617F variant in myeloproliferative disorders allowing their reclassification in a new nosological group. | 07-25-2013 |
20130184685 | METHOD FOR PREPARING RED BLOOD CELLS FOR INFUSION - The present invention relates to methods to prepare red blood cells (RBCs) for infusion to a patient. Depletion of RBCs with altered deformability is achieved by filtration through micro-bead filters. | 07-18-2013 |
20130184293 | COMPOSITIONS AND METHODS FOR TREATING DIABETES AND NEUROPSYCHOLOGICAL DYSFUNCTION - The present invention relates to compositions and methods for treating diabetes mellitus, neuropsychological and neurological disorders in a particular group of patient. More specifically, the invention relates to methods of treating diabetes mellitus, neuropsychological and neurological disorders in patients having defective potassium channels. The invention may be used in human subjects, particularly adults or children, and is appropriate to treat various neurological disorders. | 07-18-2013 |
20130183706 | Method for Culturing Adipocytes - The present invention relates to a method for culturing adipocytes, in which a homogeneous population of mature adipocytes isolated from adipose tissue is cultured on a three-dimensional culture substrate. | 07-18-2013 |
20130157301 | Diagnosis of bacterial meningitis based on the measure of ROS production in a sample of cerebrospinal fluid - The present invention pertains to a method for in vitro diagnosing a bacterial infection in a biological fluid selected amongst cerebrospinal fluid, ascitic fluid, pericardial fluid, pleural fluid, urine and synovial fluid, based on the measure, in a sample of said fluid, of the production of reactive oxygen species (ROS); a high level of ROS production is indicative of the presence of activated polymorphonuclear neutrophils (PMNs) in said fluid, which in turn is a hallmark of bacterial infection. | 06-20-2013 |
20130095133 | PHARMACEUTICAL COMPOSITIONS COMPRISING A POLYPEPTIDE COMPRISING AT LEAST ONE CXXC MOTIF AND HETEROLOGOUS ANTIGENS AND USES THEREOF - The invention relates to pharmaceutical compositions using a polypeptide comprising at least one CXXC motif, such as | 04-18-2013 |
20130084334 | PHARMACEUTICAL COMPOSITIONS HIGHLY DOSED WITH BIOTIN - The invention relates to novel pharmaceutical compositions highly dosed with biotin, as well as to the use thereof in treating visual impairments which are related, in particular, to optic atrophy. | 04-04-2013 |
20130040832 | IDENTIFYING VIRAL CELL TROPISM - The invention relates to an in vitro method for identifying microRNAs or the target mRNAs thereof, the expression of which during the infection of cells by a virus using a cell receptor and at least one cell co-receptor for entering the cell, is specifically modified on the basis of the cell co-receptor used by the virus for its entering the cells, comprising:
| 02-14-2013 |
20130029863 | METHOD FOR DETECTING MICROORGANISMS - The invention relates to the diagnostic field and to the characterization of antibiotic-resistant bacteria in a sample by detecting specific nucleotides in the CMY-2 gene. | 01-31-2013 |
20120308668 | MAZINDOL COMBINATION IN THE TREATMENT OF ATTENTION DEFICIT/HYPERACTIVITY - The present invention relates to the field of human health, and more particularly to the treatment of attention deficit/hyperactivity disorder (ADHD) with mazindol. The latter can be administered as monotherapy or in combination with one or more compounds, including psychostimulants, for the indication of ADHD and associated or co-morbid symptoms. | 12-06-2012 |
20120308515 | USE OF GILZ PROTEIN EXPRESSED IN DENDRITIC CELLS TO MODULATE AN ANTIGEN-SPECIFIC IMMUNE RESPONSE - A pharmaceutical composition comprising at least dendritic cells modified with a molecule selected from the group consisting of: a GILZ protein or a functional fragment of at least 5 consecutive amino acids of said protein; a small interfering RNA (siRNA) targeting the GILZ transcript or an antisense oligodeoxynucleotide complementary to said transcript; and a recombinant expression vector containing a polynucleotide encoding said GILZ protein, said fragment, said siRNA or said antisense oligodeoxynucleotide complementary to said transcript and a pharmaceutically acceptable carrier. In addition, a method for treatment of autoimmune diseases, inflammatory diseases, allergies, transplant rejection and graft-versus-host disease, cancers or pathogenic microorganism infections by administering an effective amount of said pharmaceutical composition to a subject in need thereof. | 12-06-2012 |
20120302517 | TET2 AS A NEW DIAGNOSTIC AND PRONOSTIC MARKER IN HEMATOPOIETIC NEOPLASMS - The present invention concerns an in vitro method for diagnosing a myeloid tumour or a lymphoid tumour in a subject, which comprises the step of analyzing a biological sample from said subject by (i) detecting the presence of a mutation in the Ten Eleven Translocation protein family member 2 gene (TET2) coding for the polypeptide having the sequence SEQ ID NO:2, and/or (ii) analyzing the expression of the TET2 gene; wherein the detection of such a TET2 mutation, of the absence of expression of TET2 or of the expression of a truncated TET2 is indicative of a subject developing or predisposed to develop a myeloid tumour or a lymphoid tumour. | 11-29-2012 |
20120296404 | INTRACEREBRAL ELECTRODE - An intracerebral electrode ( | 11-22-2012 |
20120282167 | METHOD FOR PREDICTING THE SENSITIVITY OF A TUMOR TO AN EPIGENETIC TREATMENT - The present invention provides a method for determining the RES phenotype in a tumor. The present invention further provides a method for predicting the sensitivity of a tumor to an epigenetic treatment, the method comprising determining the RES phenotype in said tumor, the presence of the RES phenotype in a tumor being indicative of a tumor sensitive to an epigenetic therapy. The present invention also provides a method for diagnosing an aggressive tumor and for selecting a patient affected with a tumor for an epigenetic therapy. | 11-08-2012 |
20120276577 | Method for Determining the Susceptibility of a Cell Strain to Drugs - The present invention relates to a method for determining the susceptibility of a cell strain to a compound intended for controlling the growth of said cell strain, comprising:
| 11-01-2012 |
20120264165 | METHOD OF DETECTING TUMOR CELLS BY FLUORESCENCE SIGNALS - The invention relates to a method of detecting dividing cells, or cells having the potential of dividing, in a cytological specimen stained using a Papanicolaou staining process, by the detection of a fluorescence signal coming from the membranes of these cells. | 10-18-2012 |
20120230937 | IMPLANTABLE BIO-RESORBABLE POLYMER - The present invention relates to a polymer obtained from the polymerization of: (i) at least one monomer of formula (I) (CH | 09-13-2012 |
20120226181 | Non-Invasive Method for Assessing Tissue Perfusion in a Patient - The present invention pertains to a non-invasive way of assessing tissue perfusion in a patient, especially for treatment follow-up and prognosis of septic shock. More specifically, tissue perfusion is assessed by measuring the cutaneous partial pressure of carbon dioxide of said patient, for example at ear lobe with a PCO | 09-06-2012 |
20120225947 | RETINAL NEUROPROTECTION BY ION CHANNEL BLOCKERS REGULATED BY THE SUR SUBUNIT - The present invention relates to the use of blockers of ion channels regulated by the SUR subunit, for the treatment and/or prevention of eye diseases associated with ischemia and/or retinal excitotoxicity. | 09-06-2012 |
20120195826 | INJECTABLE BIOMATERIAL - The invention relates to an injectable biomaterial. The injectable biomaterial of the invention comprises a non aqueous solvent which is compatible for injection to human being and nanoparticles made of a polymer which is insoluble in water and insoluble in said non aqueous solvent, said nanoparticles being loaded with a drug or a biological agent. The injectable biomaterial of the invention is particularly appropriate for occluding normal or malformative blood vessels or non circulating cavities or for necrosing tumors. | 08-02-2012 |
20120172707 | METHOD FOR DEVELOPING AN INFORMATION PREDICTION DEVICE, USE THEREOF, AND CORRESPONDING STORAGE MEDIUM AND APPARATUS - A method for developing a prediction device for predicting a phenotype of a person from imaging data of the person is provided. The method includes determining imaging descriptors, the determining imaging descriptors including acquiring multidimensional images of people with an imaging apparatus and extracting multidimensional image elements from the acquired multidimensional images to serve as descriptors The method also includes classifying the predetermined descriptors on the basis of the capability thereof to predict the phenotype, selecting, from among the classified descriptors, a relevant number of the best-classified descriptors that is sufficient to predict the phenotype and constructing the prediction device from the selected descriptors. | 07-05-2012 |
20120172660 | Catheter, In Particular for Implanting an Embryo in the Uterine Cavity of a Human Being or Animal, and Corresponding Instrument - This catheter ( | 07-05-2012 |
20120145156 | PHONATION ASSISTANCE DEVICE FOR A TRACHEOTOMY PATIENT - The invention relates to a phonation assistance device for a tracheotomy patient, including: an exhalation circuit connected to a tracheotomy cannula inserted in the trachea of the patient, the exhalation circuit including an outlet opening for the passage of the air exhaled by the patient; and a valve for opening/closing the outlet opening for normally assuming, when the patient inhales, a position for closing the outlet opening and, when the patient exhales, a position for closing the outlet opening. It also includes means for the positive priority control of the valve for selectively moving the valve into the closed position when the patient exhales. | 06-14-2012 |
20120115171 | Method For Diagnosing Thrombophilia - The invention relates to a method for diagnosing thrombophilia in a subject suffering from HIV or from a systemic auto-immune disease, said method comprising determining in a blood sample obtained from said subject the level of free Protein S having Activated Protein C (APC) cofactor activity and the level of total Protein S. | 05-10-2012 |
20120095742 | SYSTEM AND METHOD FOR PROCESSING SIGNALS FOR THE REAL-TIME DETECTION OF A FUNCTIONAL CYCLIC ACTIVITY - A system and method for processing signals for the real-time detection of a functional cyclic activity, include: elements for simultaneously receiving signals acquired by a sensor array having at least two sensors; elements for recording and preprocessing the acquired signals during a plurality of consecutive cycles; elements for identifying event combinations from the recordings of the acquired signals, enabling a calibration to be carried out, including: elements for identifying a plurality of events in the acquired signals, each signal including an identified event; elements for defining a model of the functional activity, consisting of a time order of the events and the mean delays between the events, and elements for defining a detection time window from the functional activity model. | 04-19-2012 |
20120095082 | USE OF INTERFERING RNA FOR TREATING AN HIV INFECTION - The present invention relates to interfering RNAs, in particular miRNAs, capable of specifically blocking the replication of a strain of the HIV virus that is resistant to an antiretroviral compound, and use thereof for treating infections by this type of virus. | 04-19-2012 |
20120094273 | IMMUNOLOGICAL METHOD FOR DETECTING ACTIVE JCV INFECTION - The invention relates to an immunological method for detecting an extra renal active infection by JC virus in a patient candidate for a treatment with an immunosuppressive treatment or during the course of this treatment. | 04-19-2012 |
20120088715 | MUTATED ANTITHROMBINS, A PROCESS FOR PREPARING THE SAME AND THEIR USE AS DRUGS - The present invention relates to the use of a composition including of at least a mutated antithrombin
| 04-12-2012 |
20120088257 | METHOD FOR DIAGNOSING VASCULITIS - The invention relates to a method for the in vitro detection of vasculitis or the risk of developing vasculitis, including determining the presence and/or the amount of anti-endothelial cell antibodies (AECA) or anti-vascular smooth muscle cell (VSMC) antibodies in a biological sample from a patient. | 04-12-2012 |
20120070855 | METHOD FOR IN VITRO ASSAY OF SOLUBLE FIBRIN BY GENERATING SPECIFIC DEGRADATION PRODUCTS - The invention concerns a method for assaying soluble fibrin in a sample, in which said sample is brought into the presence of a plasminogen activator with a high specificity for soluble fibrin (PA-Fb sp) and the soluble fibrin count in the sample is measured by measuring the difference between the count of fibrin degradation products obtained after degrading soluble fibrin with PA-Fb sp and the base count of fibrin degradation products determined before bringing the sample into the presence of PA-Fb sp. | 03-22-2012 |
20120066776 | IDENTIFICATION OF A JAK2 MUTATION INVOLVED IN VAQUEZ POLYGLOBULIA - The present invention concerns the V617F variant of the protein-tyrosine kinase JAK2, said variant being responsible for Vaquez Polyglobulia. The invention also relates to a first intention diagnostic method for erythrocytosis and thrombocytosis allowing their association with myeloproliferative disorders, or to the detection of the JAK2 V617F variant in myeloproliferative disorders allowing their reclassification in a new nosological group. | 03-15-2012 |
20120058936 | COMPOSITIONS AND METHODS FOR ELIMINATION OF GRAM NEGATIVE BACTERIA - Oral drug delivery formulations which specifically administer antibacterial agents to the ileum, caecum, and/or the colon, without significant administration elsewhere in the gastrointestinal tract, are disclosed. The formulations include, as actives, a combination of a macrolide or aminoglysoside, or quinolone antibacterial and an anti-Gram-negative lipopeptide (polymyxin) antibacterial agent or other peptide antibacterials effective against Gram-negative bacteria. The formulations can be used to treat infections or unwanted colonization in the colon, and to provide effective decontamination of the colonic flora from unwanted or potentially pathogenic bacteria. | 03-08-2012 |
20120034167 | TYROSINE KINASE RECEPTOR TYRO3 AS A THERAPEUTIC TARGET IN THE TREATMENT OF CANCER - The present invention concerns new methods for treating cancer by using TYRO3 inhibitors and methods for identifying new molecules of interest for treating cancer. | 02-09-2012 |
20120014933 | Method for Producing Platelets - The present invention relates to a method for producing platelets from mature megakaryocytes. More particularly, the invention relates to an ex vivo method for producing platelets, from mature megakaryocytes, said method comprising a step of subjecting a suspension of mature megakaryocytes to a flow having a minimal shear rate of 600 s | 01-19-2012 |
20110319870 | METHOD FOR INCREASING THE POOL OF NGN3+ ENDOCRINE PROGENITOR CELLS AND PANCREATIC ENDOCRINE CELL MASS - The present invention discloses a method for increasing the pool of Ngn3+ endocrine progenitor cells obtained from stem cells, by contacting said stem cells with a SUR1/Kir6.2 channel inhibitor. The invention also relates to a method for increasing the mass of pancreatic endocrine cells, in particular of β cells. The invention further concerns a method for treating diabetes. | 12-29-2011 |
20110301481 | SYSTEM FOR QUANTIFYING THE DISCREPANCY BETWEEN A PATIENT RECEIVING ASSISTED BREATHING AND A CORRESPONDING ASSISTANCE DEVICE - This system is characterized in that includes:
| 12-08-2011 |
20110269637 | Method for Predicting Clinical Outcome of Patients With Non-Small Cell Lung Carcinoma - The invention provides an in vitro method for predicting clinical outcome of a patient affected with a non-small cell lung carcinoma (NSCLC), which method comprises determining the expression level of at least 8 genes in a biological sample of said patient. | 11-03-2011 |
20110263998 | SYSTEM FOR DETECTING RESPIRATORY MUSCLE ACTIVITY OF A PATIENT RECEIVING ASSISTED BREATHING - The invention relates to a system for detecting respiratory muscle activity of a patient ( | 10-27-2011 |
20110229900 | METHOD FOR DETECTING MICROORGANISMS OF KINGELLA GENUS - The invention relates to a method for detecting Kingella microorganisms through PCR of a chaperonin gene. | 09-22-2011 |
20110183009 | Mazindol Combination In The Treatment Of Attention-Deficit/Hyperactivity - The present invention relates to the field of human health, and more particularly to the treatment of attention deficit/hyperactivity disorder (ADHD) with mazindol. The latter can be administered as monotherapy or in combination with one or more compounds, including psychostimulants, for the indication of ADHD and associated or co-morbid symptoms. | 07-28-2011 |
20110130830 | AORTIC RING AND ANCILLARY DEVICE FOR IMPLANTING IT - Aortic ring ( | 06-02-2011 |
20110129840 | METHOD, PROCESS, AND KIT FOR DIAGNOSIS OR PROGNOSIS OF COLORECTAL CANCER - A process or method and a kit for the diagnosis/prognosis and follow-up of colorectal cancer, which includes a) the extraction of nucleic material from a biological sample, b) use of at least one pair of amplification primers in order to obtain amplicons of at least one target sequence, and c) use of at least one detection probe to detect the presence of the amplicons, the process or method including a modification step between steps 1) and b). Steps b) and c) are carried out at the same time. The target sequence is included in the WIF1 gene and the pair of primers includes at least one amplification primer including at least 15 nucleotide patterns of a nucleotide sequence selected from SEQ ID nos. 1 to 10 and/or the detection probe includes at least 15 nucleotide patterns of a nucleotide sequence selected from SEQ ID nos. 1 to 10. | 06-02-2011 |
20110124723 | Compounds for Preventing and Treating Plasmodium Infections - The present invention relates to the use of at least one compound of formula (I) for the manufacture of a medicament intended for preventing or treating infections by a | 05-26-2011 |
20110086805 | IN VITRO METHOD FOR DIAGNOSING SKIN CANCER - The present invention relates to an in vitro method for identifying an individual suffering from or having a predisposition to skin cancer, characterized in that it comprises the step of analysing a biological sample originating from said individual by a) detecting a polymorphism of the MATP/SLC45A2 gene (SEQ ID NO: 1), and/or analysing the expression of the MATP/SLC45A2 gene; to the use, for preparing a composition for the treatment and/or prevention of a skin cancer in an individual, of a compound which specifically increases the expression of the MATP/SLC45A2 gene in a skin cell; and to a method for the selection, in vitro, of a compound capable of being of use in the treatment of skin cancer. | 04-14-2011 |
20110071385 | METHOD AND SYSTEM FOR LOCALIZING AN INGESTIBLE ELEMENT FOR THE FUNCTIONAL INVESTIGATION OF THE DIGESTIVE TRACT - A non-invasive exploration method for assessing the digestive motility of a subject including the subject swallowing an ingestible transmitting element containing a transmission means transmitting at a given fixed frequency, measuring in series the phase-shift of the frequency transmitted by each of at least three transportable reception means relative to a reference phase of a reference beacon to fix the origin of a coordinates system and the coordinates of each transportable reception means. Each of the reception means including a transceiver where the reception means is distributed around the subject and the reference beacon is attached to a given fixed location on the subject. The method includes measuring the phase shift of the frequency transmitted by the transmission means of the ingestible element to obtain at least three phase-shift measurements and determining by triangulation based on the phase-shift measurements a position of the ingestible element in the coordinates system. | 03-24-2011 |
20110059184 | MEDICAMENT FOR TREATING PARKINSON'S DISEASE - The invention relates to the manufacture of a unit dose of a medicament for relieving the symptoms and/or restoring and/or protecting the neurons of patients suffering from Parkinson's disease. According to the invention, bee's venom is used in an amount of between 33 and 330 micrograms inclusive, for the manufacture of a unit dose for subcutaneous injection, every one to six weeks, of a medicament for relieving the symptoms and/or restoring and/or protecting the neurons of patients suffering from Parkinson's disease. The invention finds use in particular in the field of pharmacy. | 03-10-2011 |
20110044906 | Methods for the Treatment, the Prognostic Assessment and the Staging of Non-Small Cell Lung Cancer - The present invention relates to methods for the treatment, the prognosis and the diagnosis of non-small cell lung cancer. | 02-24-2011 |
20110014691 | METHOD FOR GENERATING PRIMATE CARDIOVASCULAR PROGENITOR CELLS FOR CLINICAL USE FROM PRIMATE EMBRYONIC STEM CELLS OR EMBRYONIC-LIKE STATE CELLS, AND THEIR APPLICATIONS - The present invention is directed to a method for the in vitro preparation of cardiovascular progenitors cells from mammalian embryonic stem cells (ES cells) or mammalian embryonic-like state cells, preferably from primate, wherein said method comprises the use of the CD15 (SSEAI) marker as a positive cardiovascular progenitors differentiation marker. The present invention also claimed the use of a receptor tyrosine kinase inhibitor, particularly the SU5402 or SU11248 in association with the BMP2 for improving the efficiency of the desired differentiation. The present invention is also directed to the use of platelet lysate as foetal animal serum substitute in a culture medium intended to the proliferation or propagation of primate ES cells maintaining their pluripotency feature. Derived compositions or kits in relation with the claimed methods or product obtainable by the claimed methods form also part of the present invention. | 01-20-2011 |
20110009330 | MEDICAMENT FOR TREATING PARKINSON'S DISEASE - The invention relates to the manufacture of a unit dose of a medicament for relieving the symptoms and/or restoring and/or protecting the neurons of patients suffering from Parkinson's disease. According to the invention, apamine is used in an amount of between 1 and 10 micrograms inclusive, for the manufacture of a unit dose for subcutaneous injection, every one to six weeks, of a medicament for relieving the symptoms and/or restoring and/or protecting the neurons of patients suffering from Parkinson's disease. The invention finds use in particular in the field of pharmacy. | 01-13-2011 |
20100215629 | TREATMENT OF TUMORS USING T LYMPHOCYTE PREPARATIONS - The invention relates to the treatment of a tumor in a patient, by injecting T lymphocytes depleted of regulatory T lymphocytes, and expressing a molecule allowing their specific destruction, the patient receiving beforehand a non-myeloablative or myeloablative lymphopenic treatment. | 08-26-2010 |
20100209903 | Method for measuring resistance of a patient HIV-2 to protease inhibitors - A search method in a biological sample containing an HIV-2 viral strain for possible resistance of said strain to treatment by an anti-protease agent, and nucleotide probes for the implementation thereof. According to methods known per se, the presence of at least one mutation at certain, specified, particular positions of the proteinic sequence of the protease of said viral strain from a biological sample taken from a patient contaminated by HIV-2 is searched. If said mutation is observed, the existence of a resistance to said anti-protease agent is assumed in the patient. | 08-19-2010 |
20100196417 | COMPOSITIONS COMPRISING A B SUBUNIT OF SHIGA TOXIN AND A MEANS STIMULATING NKT CELLS - The present invention relates to a composition comprising a) a B subunit of Shiga toxin or a functional equivalent thereof which is able to bind the Gb3 receptor, complexed with an antigen and b) at least one ligand of CDI capable of stimulating NK T cells; and to a pharmaceutical composition and a medicament comprising said composition. | 08-05-2010 |
20100183555 | METHODS AND KITS FOR DETERMINING DRUG SENSITIVITY IN PATIENTS INFECTED WITH HCV - An in vitro method for determining whether a patient infected with HCV is a responder or non-responder to the treatment with interferon-alpha and ribavirin. More specifically, the method includes a step of determining the expression level of the IFI27, CXCL9 and G1P2 genes in a biological sample. | 07-22-2010 |
20100167273 | Method for Selectively Quantifying Vegf Isoforms in a Biological Sample and Uses Thereof - The present invention pertains to a novel method for quantifying VEGF various isoforms in a biological sample, with a very high selectivity and sensitivity. It also concerns a method for establishing a diagnostic and/or a prognosis concerning a patient potentially suffering from cancer, diabetes, or cardiovascular disease, comprising a step of determining the level of at least one of the VEGF isoforms, in a biological sample from said patient. | 07-01-2010 |
20100166737 | P38Alpha as a Therapeutic Target in Bladder Carcinoma - The present invention concerns methods and compositions for treating bladder carcinoma by p38 inhibitors. | 07-01-2010 |
20100145728 | INTEROPERABILITY PLATFORM - The present application relates to a computer system for processing customized medical records comprising dedicated equipment for the acquisition of specialized information, as well as, for each healthcare facility, of aggregation equipment for the centralization of the information in view of delivering a customized medical record formed from information coming from said dedicated equipment, and for the distribution of the customized medical records to various operators acting on behalf of at least one healthcare network, characterized in that it comprises an interoperability platform having computer connectors configured for the exchanges between said interoperability platform and each of the aggregation equipment of said healthcare facilities, and computer connectors configures for the exchanges between said interoperability platform and each of said operators, wherein said platform comprises means for conditional routing to one of said operators depending on the information registered in relation to the digital file corresponding to the customized medical record and means for transcoding said file according to the nominal format of said target operator. | 06-10-2010 |
20100143894 | Quantitative Detection of Hdv by Real-Time Rt-Pcr - Specific reagents for quantitative assay of HDV and more specifically to follow HDV viral load in chronically infected patients and such a quantitative assay. | 06-10-2010 |
20100131286 | METHODS FOR THE PROGNOSIS OR FOR THE DIAGNOSIS OF A THYROID DISEASE - The present invention relates to methods for predicting or diagnosing a thyroid disease in an individual. | 05-27-2010 |
20100094406 | ENDOPROSTHESIS, AND METHOD FOR PRODUCING AN ENDOPROSTHESIS - The endoprosthesis is designed to be implanted in an aneurysm ( | 04-15-2010 |
20100093863 | USE OF CITRULLINE FOR PREVENTING AN INCREASE IN PROTEIN CARBONYLATION AND FOR TREATING DISEASES RESULTING THEREFROM - A method of using L-citrulline of the formula (I) for preparing a cosmetic composition, a food or nutraceutic composition or a pharmaceutical composition for treating diseases related to an increase in protein carbonylation, in particular for treating neurodegenerative diseases such as Alzheimer's or Parkinson's disease. | 04-15-2010 |
20100015219 | PHARMACEUTICAL COMPOSITIONS OF ACTIVE SUBSTANCES DIFFICULT TO IMPROPERLY DIVERT FROM THEIR INTENDED ROUTE OF ADMINISTRATION - A solid pharmaceutical composition in the form of a gel capsule containing at least one active ingredient and also at least one gelling agent chosen from cellulose derivatives such as hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, methylcellulose, ethylmethylcellulose, sodium carboxymethylcellulose (CMC) and calcium carboxymethylcellulose, and at least one disintegrating agent, the gelling agent and the disintegrating agent being present in a ratio by weight of 0.3 to 0.7/1 and the content by weight of gelling agent(s) being from 10% to 20% of the composition, and method for preparing same. | 01-21-2010 |
20090325194 | USE OF SPLA2 ACTIVITY FOR THE DIAGNOSIS OF A CARDIOVASCULAR EVENT - A method for determining an increased risk of mortality or of a cardiac and/or vascular event in a patient, includes:—determining the sPLA2 activity of the patient as a first risk marker—determining at least the value of a second risk marker chosen among CRP level, IgM IC of apo B 100 level or IgM MDA-LDL level—determining the ratio (odds ratio) between the value of the sPLA2 activity and the value of the second risk marker and comparing it to a predetermined odds ratio, the odds ratio compared to the predetermined odds ratio being indicative of an increased risk of mortality or of a cardiac and/or vascular event. A new micro method adaptation for automated fluorimetric measurement of serum secretory phospholipase A2 is also disclosed. | 12-31-2009 |
20090306212 | Compositions and Methods for Treating Diabetes and Neuropsychological Dysfunction - The present invention relates to compositions and methods for treating diabetes mellitus, neuropsychological and neurological disorders in a particular group of patient. More specifically, the invention relates to methods of treating diabetes mellitus, neuropsychological and neurological disorders in patients having defective potassium channels. The invention may be used in human subjects, particularly adults or children, and is appropriate to treat various neurological disorders. | 12-10-2009 |
20090298713 | POLYNUCLEOTIDES WHICH ARE OF NATURE B2/D+ A- AND WHICH ARE ISOLATED FROM E. COLI, AND BIOLOGICAL USES OF THESE POLYNUCLEOTIDES AND OF THEIR POLYPEPTIDES - The present invention relates to products which are of nature B2+ A−, isolated from | 12-03-2009 |
20090269310 | METHOD FOR OBTAINING HUMAN SMOOTH MUSCULAR CELLS AND USES THEREOF - The invention concerns a method for obtaining in vitro a population of cells comprising essentially human smooth muscular cells expressing calponin and SM-MHC from a sample of human muscular biopsy or from human muscular biopsies differentiated in vitro into skeletal muscle cells. The invention also concerns a composition comprising the isolated smooth muscular cells obtainable by said method as therapeutic principle designed for humans. The invention further concerns the use of the isolated smooth muscular cells for preparing a therapeutic composition designed to replace smooth muscular cells. In particular, the invention concerns the use of said isolated smooth muscular cells for treating ischemia, cancer or any disease requiring revascularization of damaged tissues. Finally, the invention concerns the use of said smooth muscular cells as vector for an active principle for preparing a therapeutic composition designed for humans requiring treatment with said active principle. | 10-29-2009 |
20090253122 | Method for measuring resistance of a patient HIV-2 to protease inhibitors - A search method in a biological sample containing an HIV 2 viral strain for possible resistance of said strain to treatment by an anti-protease agent, and nucleotide probes for the implementation thereof. According to methods known per se, the presence of at least one mutation at certain, specified, particular positions of the proteinic sequence of the protease of said viral strain from a biological sample taken from a patient contaminated by HIV 2 is searched. If said mutation is observed, the existence of a resistance to said anti-protease agent is assumed in the patient. | 10-08-2009 |
20090202992 | POLYNUCLEOTIDE AND PROTEIN INVOLVED IN SYNAPTOGENESIS, VARIANTS THEREOF, AND THEIR THERAPEUTIC AND DIAGNOSTIC USES - The invention relates to a kit for diagnosing autism linked to a mutation in a protein belonging to the family of human neuroligins. | 08-13-2009 |
20090136533 | POLYPEPTIDE DERIVED FROM gp41, A VACCINE COMPOSITION COMPRISING SAID POLYPEPTIDE, AND USES FOR TREATING AN INFECTION BY AN HIV VIRUS IN AN INDIVIDUAL - The present invention relates to the field of the in vitro diagnosis of the progression status of an infection of an individual with a virus belonging to the family of the Human Immunodeficiency Viruses (HIV) as well as with the therapeutical treatment of this infectious disease. The invention also relates to immunological compounds and vaccine compositions comprising a polypeptide derived from gp41. | 05-28-2009 |
20090117554 | POLYNUCLEOTIDE AND PROTEIN INVOLVED IN SYNAPTOGENESIS, VARIANTS THEREOF, AND THEIR THERAPEUTIC AND DIAGNOSTIC USES - The invention relates to a method and a kit for diagnosing autism linked to a mutation in a protein belonging to the family of human neuroligins. | 05-07-2009 |
20090117110 | Method for the In Vitro Assessment of the Progression Status of an Infection by an HIV Virus in an Individual - The present invention relates to the field of the in vitro diagnosis of the progression status of an infection of an individual with a virus belonging to the family of the Human Immunodeficiency Viruses (HIV) as well as with the therapeutical treatment of this infectious disease. | 05-07-2009 |
20090028875 | USE OF GILZ PROTEIN EXPRESSED IN DENDRITIC CELLS TO MODULATE AN ANTIGEN-SPECIFIC IMMUNE RESPONSE - The invention concerns the use of at least one: a) a GILZ protein, a functional fragment of at least 5 consecutive amino acids of said protein, a GILZ modulator, or a recombinant vector expressing same, isolated or expressed in modified dendritic cells, and b) an antigen of interest and/or a molecule allowing targeting and/or passage of the plasmic membrane of dendritic cells, to prepare a medicine for preventing and/or treating autoimmune, inflammatory diseases, allergies, graft rejection and graft-versus-host disease, cancers and pathogenic micro-organism infections. | 01-29-2009 |
20080261212 | Method of Diagnosis/Prognosis of Human Chronic Lymphocytic Leukemia Comprising the Profiling of Lpl/Adam Genes - The present invention provides methods of diagnosis and prognosis of human chronic lymphocytic leukemia (CLL) in a patient in need thereof and methods to determine IgVH mutational status. The methods of the present invention involve measuring the expression profile of two known genes: LPL and ADAM29; and comparing the ratio of their expression to diagnose the presence of CLL or to prognose the likelihood of developing CLL or the symptoms consistent with CLL. | 10-23-2008 |
20080200817 | Electronic Polarimetric Imaging System for a Colposcopy Device and an Adapter Housing - The invention relates to an electronic polarimetric imaging system use in a colposcopy device for in vivo monitoring a cervix, which is provided with a light source for illuminating the observable cervix and at least visual means for monitoring said cervix, wherein the illumination optical path directed to the cervix and the image optical path coming back from the cervix are separated from each other on at least a portion of the paths thereof. The inventive system comprises a polarimetric adapter housing which is removable in the separated portion of the illumination and image optical paths and comprises a polarization state generator (PSG) positioned on the illumination optical path and a polarization analyser (PSA) positioned on the image optical path, wherein said polarization state generator (PSG) and polarization analyser (PSA) are designed in such a way that they are controllable. Said invention makes it possible to obtain several polarimetric characterisation levels. The adapter housing is also disclosed. | 08-21-2008 |
20080199397 | Use of a Tetrapeptide Acsdkp Analogue Resistant to the Angiotensin i Conversion Enzyme, for Measuring Glomerular Filtration Rate in a Human or an Animal and Kit Containing Same - The invention concerns the use of ACE-resistant N-acetyl-Ser-Asp-Lys-Pro analogues for preparing a reagent or marker adapted to measure a glomerular filtration rate. | 08-21-2008 |